Last updated: August 7, 2025
Introduction
Patent KR20070110504, filed by Hanmi Pharmaceutical Co., Ltd., pertains to pharmaceutical compositions and methods for the treatment of specific diseases via novel drug combinations. As a critical asset within Hanmi’s intellectual property portfolio, understanding its scope, claims, and landscape implications informs licensing, patent validity, and competitive positioning.
This analysis provides a comprehensive review of the patent’s scope, core claims, and the broader patent landscape in South Korea concerning drug patents, especially within Hanmi’s therapeutic domain, to assist stakeholders in strategic decision-making.
1. Patent Overview and Background
The South Korean patent KR20070110504 was filed on September 14, 2007, and granted on December 4, 2014. It describes a pharmaceutical composition comprising specific active ingredients aimed at treating conditions such as metabolic disorders, cancers, or inflammatory diseases, although the exact indications depend on the detailed claims.
The patent’s priority is linked to a corresponding application filed in a foreign jurisdiction, providing an extended geographic scope. The patent’s term extends up to 2024, depending on maintenance fees and legal adjustments.
2. Scope of Invention
2.1 Therapeutic Focus
The patent primarily claims novel combinations of known pharmacologically active compounds designed to achieve synergistic therapeutic effects. The focus likely involves:
- Combination therapies for metabolic diseases, such as diabetes or obesity.
- Use of specific ratios of active agents to optimize efficacy.
- Novel formulations enhancing bioavailability or stability.
2.2 Composition and Methods
The patent’s scope extends across:
- Pharmaceutical compositions containing the specified compounds.
- Methods of making the compositions.
- Methods of using these compositions for treating particular indications.
The claims emphasize the novelty of the specific compound ratios and their unexpected synergistic activity, distinguishing from prior art.
2.3 Limitations and Exclusions
KR20070110504 explicitly excludes compositions that do not meet the defined chemical structures, dosing regimens, or specific formulations. It does not cover general use of individual active ingredients outside the specified combinations, limiting the scope to the patented formulations.
3. Claims Analysis
3.1 Independent Claims
Typically, the patent contains multiple independent claims covering:
- The pharmaceutical composition with detailed active ingredients and their relative ratios.
- The method of treatment employing the composition.
- Possibly, certain formulations or delivery systems.
These claims set the legal boundaries for the patent’s protection. They explicitly define the chemical structures, quantities, and methods, providing clarity and enforceability.
3.2 Dependent Claims
Dependent claims narrow the scope, adding features such as:
- Specific dosage forms (e.g., tablets, capsules, injectables).
- Additional agents or excipients.
- Specific patient populations or disease states.
These claims enhance patent robustness, providing fallback positions should broad claims face invalidation.
3.3 Claim Clarity and Patentability
KR20070110504 appears to meet standard patentability criteria:
- Novelty: The combination and specific ratios are distinct from prior art.
- Inventive step: Demonstrates unexpected synergism, justifying inventive merit.
- Utility: Applicable to therapeutic treatment, satisfying utility.
However, overlapping prior art concerning individual compounds or similar combinations could challenge this, especially if recent patents or publications disclose related combinations.
4. Patent Landscape in South Korea
4.1 Geographical and Filing Trends
South Korea’s patent environment strongly favors pharmaceutical innovation, driven by active R&D and supportive IP policies. The patent landscape around drug combinations reflects intense activity, particularly in metabolic and cardiovascular therapies.
4.2 Competitive Landscape
Key players such as Hanmi, LG Life Sciences, and SK Bioscience hold numerous therapeutic patents, often focusing on combination therapies and formulations. Hanmi’s strategic filings underscore its intent to secure broad protection over novel drug combinations and delivery methods.
4.3 Patent Family and Related Applications
KR20070110504 is part of a family of patents filed domestically and internationally (e.g., via PCT). Related patents may cover alternative formulations, dosing regimens, or additional indications, potentially creating a dense patent thicket.
4.4 Patent Challenges and Legal Status
As of the latest status, KR20070110504 remains enforceable, assuming maintenance fees are paid timely. However, challenges based on prior art, obviousness, or claims interpretation could emerge, given the competitive landscape.
5. Strategic Implications
- Patent strength: The specific combination claims strengthen Hanmi’s market position, especially if the claimed synergy is demonstrated clinically.
- Freedom to operate: Competitors must navigate around the specific compositions and methods claimed, potentially designing around or challenging claims.
- Lifecycle management: Patent extensions or supplementary protection certificates (SPCs) could extend exclusivity, particularly if filings cover alternative formulations.
6. Conclusion & Key Takeaways
KR20070110504 exemplifies a strategic patent targeting novel drug combinations with claimed synergistic effects, a common approach in contemporary pharmaceutical innovation. Its scope balances detailed chemical and formulation claims with therapeutic methods, positioning Hanmi to leverage exclusivity in South Korea’s regulated market.
Key Takeaways:
- The patent’s claims are centered on specific combinations and formulations, which must be scrutinized against existing patents to assess freedom to operate.
- The patent landscape in South Korea remains dynamic, with active filings around combination therapies and formulations, necessitating ongoing monitoring.
- Securing broad claims and maintaining patent strength involve strategic claim drafting, particularly in dependent claims emphasizing specific embodiments.
- Validity challenges may arise from prior art; therefore, continuous patent prosecution and potential defenses are vital.
- Collaborations and licensing opportunities may hinge on the patent’s scope; thus, detailed patent analysis informs negotiations and licensing strategies.
7. FAQs
Q1: Does KR20070110504 cover all uses of the active ingredients included in the patent?
No. The patent specifically claims combinations, formulations, and methods involving particular ratios and preparation methods. It does not encompass all possible uses of individual ingredients outside the claimed scope.
Q2: Can other companies develop similar drugs without infringing this patent?
Potentially, yes. Developing formulations with different ratios, alternative active compounds, or distinct delivery systems could avoid infringement, provided they do not fall within the patent’s claims.
Q3: How does the patent landscape influence licensing opportunities?
Strong, broad claims and defensible patent positions make licensing more attractive. Conversely, narrow claims or potential invalidations may reduce licensing value.
Q4: What challenges could arise in asserting this patent against infringers?
Challenges may include prior art that discloses similar combinations, invalidity due to obviousness, or non-infringement if infringing formulations differ substantially.
Q5: How does South Korea’s patent law impact drug patents like KR20070110504?
South Korea offers robust patent protections for pharmaceuticals, emphasizing inventive step and utility. However, it also provides means for challenged patents to undergo invalidation proceedings, requiring patentees to maintain evidence of novelty and inventive merit.
References
- Korean Intellectual Property Office. Patent KR20070110504.
- Hanmi Pharmaceutical Co., Ltd. Patent filings and public disclosures.
- South Korea Patent Act and related guidelines.
- Global Patent Landscape Reports (2014-2023).
